RECURSION PHARMACEUTICALS, INC. (RXRX): restructuring charge — Recursion cuts workforce ~20%, extends cash runway to Q4 2027; $11M severance charges

RECURSION PHARMACEUTICALS, INC.

Workforce reduction of ~20%; expects ~$11M in severance and related costs in 2025.
Cash runway now projected into Q4 2027; cash burn guidance <$450M in 2025, <$390M in 2026.
Expects Q2 2025 cash above $500M; includes $28M R&D tax credit and >$100M potential milestone inflows by end 2026.
Reduction part of streamlined operating strategy and post-integration transitions.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

RECURSION PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $11 million (approximately 20%).

Type: restructuring
Charge: approximately $11 million
Headcount: approximately 20%

Exact text from the filing

into the fourth quarter of 2027. These changes are expected to result in a workforce reduction of approximately 20%. The Company estimates that it will incur approximately $11 million in charges in connection with the workforce reduction, consisting of severance payments, employee benefits, and related costs, substantially all of which the Company expects to

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-138138

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.